Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis - Ekdanai Uawithya; Kamolchanok Kulchutisin; Jiraporn Jitprapaikulsan; Nattawut Leelakanok; Weerapat Owattanapanich (PLoS ONE, 2025)